The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

Children can have mild, moderate, or severe psoriasis. It's a lifelong condition ... by looking carefully at your child's skin, nails, or scalp. To be sure, they might also remove a small sample ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

In children, eczema often looks like a dry ... that causes a ring-shaped rash around the hairline. Meanwhile, scalp psoriasis tends to cause thicker, drier scales than eczema.

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

People with scalp psoriasis may experience itchy ... The infection is highly transmissible and common among young children. Although mild impetigo may clear up independently, prompt treatment ...

Some children continue to have excessive dry ... It can be difficult to tell the difference between mild scalp psoriasis and seborrhoeic dermatitis. In psoriasis there appear to be big patches ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...